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Background. Granulomatosis with polyangiitis (GPA) is an ANCA associated small vessel vasculitis characterized by necrotizing
granulomatous inflammation involving the upper and the lower respiratory tract and the kidneys. The disease has a broad clinical
spectrum that ranges from limited/localized involvement of a single organ system to a generalized systemic vasculitis that affects
several organs with evidence of end organ damage. Atypical forms of the disease have been recognized with or without respiratory
tract involvement with a long protracted course before manifesting as generalized disease. Case Presentation. We describe a 57-
year-old woman who presented with recurrent fever and cutaneous ulcers on her legs who was diagnosed to have granulomatosis
with polyangiitis (GPA) after an extensive evaluation which excluded infectious, other vasculitides, connective tissue disease and
malignant etiologies. Conclusion. In the absence of typical manifestations, granulomatosis with polyangiitis (GPA) is indeed a
diagnostic challenge to the physician. Atypical manifestations like unexplained recurrent fever and cutaneous ulcers nevertheless
call for keeping a low threshold for the diagnosis of GPA as the disease can initially present in localized form before heralding into
a generalized disease.
1. Introduction
Granulomatosis with polyangiitis (GPA) is a small vessel vas-
culitis with an array of systemicmanifestations.The hallmark
of this disease is granulomatous inflammation involving the
upper and lower respiratory tract with or without the involve-
ment of kidneys [1].However, the disease can involve virtually
any organ in the body as generalized disease or as a lim-
ited/localized disease. In the localized disease, the inflamma-
tion is confined to eyes, ears, nose, and lungs but other organs
may get involved including heart, skin, gastrointestinal tract,
and the peripheral nervous system. Cutaneous vasculitis sec-
ondary to GPA can present as papules, nodules, palpable pur-
pura, ulcers resembling pyoderma gangrenosum, or necrotiz-
ing lesions leading to gangrene [2]. There is no single lesion
specifically associated with the disease. Cutaneous lesions
are found in 50% of patients [3] but may be the presenting
symptoms in up to 10% of cases. It is therefore of utmost
importance to consider GPA in the differential diagnosis
of small vessel cutaneous vasculitis so that the disease can
be identified early in the clinical course and treated appro-
priately to prevent morbidity associated with complications
arising from generalized disease [4]. Systemic GPA can cause
life threatening diffuse alveolar hemorrhages as a result of
necrotizing alveolar capillaritis and kidney failure neces-
sitating hemodialysis due to rapidly progressive glomeru-
lonephritis [5].
Granulomatosis with polyangiitis has a strong associa-
tion with antineutrophil cytoplasmic antibodies (ANCAs)
which characteristically have a cytoplasmic labeling pat-
tern (C-ANCA) in immunofluorescence assays directed
against proteinase-3 and myeloperoxidase [6]. These are IgG
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Figure 1: Initial lesion: erythematous nodule on right shin.
antibodies directed against primary granules of the neu-
trophils and the lysosomes of monocytes [7]. ANCA can be
seen in 80–95% of the patients with generalized disease but
in limited presentations ANCA is detectable in only 60%–
80% of the cases and remains negative in 20%. Hence it is
imperative to obtain tissue biopsy for histopathological eval-
uation as amore definitivemeans to diagnose this disease [6].
2. Case Presentation
A 57-year-old woman presented to the rheumatology clinic
with recurrent fever and painful ulcers on her legs since
two months. Eight months prior to current presentation, she
developed vertigo and decreased hearing in her left ear which
she felt was “full of air” all the time. Shewas found to have sen-
sorineural deafness in her left ear. Two weeks later, she devel-
oped fever with chills. A chest radiograph revealed infiltrates
in her right lung and an elevated ESR. She was treated with
oral antibiotics which relieved her symptoms.Then she devel-
oped gingival hypertrophy and a CT scan of the paranasal
sinuses revealed subcutaneous soft tissue thickening of the
right buccal area suggestive of an inflammatory process. She
was treated with ibuprofen and felt better. Her past medical
history was notable for hypothyroidism for 20 years and she
as well was maintained on 50mcg of thyroxin daily. She had
undergone hysterectomy for uterine fibroids 15 years ago.
She reported no recent travel history. Of note, she revealed
contact with sick animals. She nursed her paralyzed pet dog
and also had cats. She was treated with antibiotics yet contin-
ued to spike fever and came to our center for comprehensive
evaluation. On examination, she appeared weak and ill. The
temperature was 37.5∘C, the blood pressure 139/69mm Hg,
the pulse 78 beats per minute, and the respiratory rate 16
breaths per minute, with 99% oxygen saturation at room air.
Erythematous tender nodules were noticed on bilateral lower
extremities (Figure 1).
The remainder of the examination was unremark-
able. Her complete blood count revealed normocytic, nor-
mochromic anemiawith normal white cell and platelet count.
Her biochemistry showed normal kidney and liver function.
No active sediment was present on urinalysis. Her three sets
of blood cultures and one urine culture reported no growth.
Table 1: Laboratory data.
Investigations Results
Hb/Hct 10.5/35
WBC 8.5 × 109/L
Platelet count 226 × 109/L
Blood urea nitrogen 12mg/dL
Serum creatinine 0.8mg/dL
Total bilirubin (direct/indirect) 0.7mg/dL (0.5/0.2)
Alanine aminotransferase 13U/L
Alkaline phosphatase 107U/L
Urinalysis
pH: 5.5, no glu-
cose/ketones/casts/protein,
WBCs 3-4/high power field
Blood cultures (3 sets) No growth
Urine culture No growth
Interferon gamma release assay
(IGRA) Negative
Brucella abortus and melitensis
titres <1 : 80 ×2
Hepatitis B surface antigen
(HBsAg) Negative
Anti-HCV antibody Negative
Antinuclear antibody Negative
Anti-dsDNA Negative
ACCP antibody Negative
QRA 27.7 (elevated)
c-ANCA Negative (0.8U/mL)
p-ANCA Negative (1.86U/mL)
Angiotensin converting enzyme 40U/L (normal <52U/L)
The test for latent tuberculosis by interferon gamma release
assay (IGRA) was also negative. Serology for Brucella abortus
andmelitensis also came negative. Tests for chronic viral hep-
atitis B and C were also normal. Serological tests for connec-
tive tissue disease were negative as was the serum angiotensin
converting enzyme level. Other relevant investigations are
outlined in Table 1. An upper abdominal ultrasound showed
hypoechoic, cystic lesions scattered across both lobes of the
liver (Figure 2). A subsequent CT scan of the abdomen with
contrast showed multiple oval hypoattenuating lesions in
both lobes of the liver (Figure 3).
On liver biopsy there was evidence of cholestasis and
multiple large irregular areas of necrosis, palisaded by epith-
eloid cells with associated granulomatous inflammation with
a number of plasma cells (Figure 4).
Acid-fast bacilli culture of liver biopsy specimen after six
weeks came out negative. Meanwhile, the patient continued
to spike feverwithmaximum temperature of 101∘F. Leg lesions
were becoming worse with central necrosis and purulent
discharge (Figures 5 and 6).
Pus cultures were negative for bacterial, fungal, and
mycobacterial growth. A biopsy of the skin was performed.
Pathological examination of frozen sections revealed surface
ulceration with fibrinoid necrosis and vasculitis involving
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Figure 2: Ultrasound upper abdomen. Multiple hypoechoic tiny
lesions on both lobes, few of them cystic in appearance.
Figure 3: CT abdomen with contrast: multiple hypoattenuating
lesions in the liver.
Figure 4: Liver biopsy. Cholestasis with multiple large areas of
necrosis palisaded by epitheloid cells with associated granulomatous
inflammation.
Figure 5: Ulceration in the nodule with erythema and discharge.
Figure 6: Ulceration progressing to central necrosis.
Figure 7: Skin biopsy. Vasculitis involving the superficial and deep
dermis showing fibrinoid necrosis of vessel wall with granuloma
formation, neutrophilic infiltrate, and nuclear debris.
superficial and deep dermal vessels along with granuloma
formation, neutrophilic infiltration, and debris (Figure 7).
Immunohistochemical testing was performed on biopsy
specimen using immune-alkaline phosphatase technique
which came negative for mycobacterial species. Real-time
PCR for mycobacterial species also turned out to be negative.
It was concluded from the skin biopsy that the patient
had cutaneous granulomatous vasculitis. Treatment was
commenced with prednisone 1mg/kg/day and the patient
was offered induction with cyclophosphamide which she
refused due to associated toxicities. Meanwhile, azathioprine
2mg/kg/day was added to prednisone. After seven weeks on
prednisone and six weeks of azathioprine her lesions had
healed almost completely (Figure 8). She was maintained on
prednisone 5mg bid and azathioprine 50mg bid with healing
lesions. A repeat CT scan of the abdomen revealed normal
architecture of hepatic parenchyma.
Therefore, considering a chronic inflammatory process
characterized by hearing loss, gingival hypertrophy, granulo-
matous hepatic lesions, and cutaneous ulcerswith necrotizing
granulomatous inflammation on skin biopsy, a unifying
diagnosis of granulomatosis with polyangiitis (GPA) was
made.
3. Discussion
Granulomatosis with polyangiitis (GPA) is complexmultisys-
temic disease with varying manifestations. The 2012 Chapel
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Table 2: Case reports of localized GPA with cutaneous manifestations.
Author and year of
publication Diagnosis Organ involvement ANCA Clinical course
Kihiczak et al. [13]
1994 Protracted superficial GPA Skin, nasal mucosa N/A
Protracted course characterized
by granulomatous skin and nasal
ulcers
Figarella et al. [14]
2000 Protracted superficial GPA
Upper respiratory tract,
skin, and lung N/A
Skin nodules on leg present for 10
years, before the diagnosis was
established based on cutaneous
histopathology
Brazzelli et al. [32]
1999 Cutaneous GPA
Acneiform nodular and
popular eruption on
forehead, dense pulmonary
infiltrates
Positive
Necrotic ulcers on forearms,
arms, and buttocks, small vessel
vasculitis of deep dermis
Kuchel and Lee [21]
2003 Cutaneous GPA
Skin involving ear lobe,
ankles, and feet Negative
Responded to prednisone and
CYC, granulomatous
inflammation on biopsy
Sinovich and Snow [33]
2003 Protracted superficial GPA
Infra-auricular skin and
nasal mucosa Positive
Pyoderma gangrenosum like
lesions with suppurative
granulomatous inflammation.
Responded to prednisone and
azathioprine
Kawakami et al. [34]
2005
GPA with cutaneous
leukocytoclastic vasculitis Skin, lung, and kidney Positive
Various cutaneous
manifestations. Palisading
neutrophilic granulomatous
dermatitis on histopathology
Ben Ghorbel et al. [35]
2007
Cutaneous and mucosal
GPA as initial presentation
in an adult
Tongue and labial ulcers,
digital necrosis, splinter
hemorrhages of fingernails,
and purpura
Positive
Diagnosis confirmed on
cutaneous and renal biopsies.
Resolution of cutaneous disease
after 6 weeks of treatment with
prednisone and CYC
Ben Ghorbel et al. [15]
2007
Recurrent digital necrotic
ulcers on fingers, toes, and
scapula as cutaneous GPA
in a child
Nasal mucosa, eyes
(keratitis), and skin Positive
Superficial ulcerations with
granulomatous vasculitis
Thaiwat and Aunhachoke
[22]
2010
Superficial GPA with
chronic scalp ulcer Skin Negative
Solitary nodule on scalp with
alopecia; nodules on left arm and
shin; purpura
Hill Consensus conference defines GPA as necrotizing gran-
ulomatous inflammation usually involving the upper and
lower respiratory tract and necrotizing vasculitis affecting
predominantly small to medium vessels [8]. However, it
is known to involve other organs with variable frequency
either as part of the “generalized” disease or as “limited” or
“localized” forms [9]. In this form, the disease does not fulfill
the diagnostic criteria early in the course but years later can
herald in a severe life threatening multiorgan form [10].
The initial symptoms in our patient were vertigo and
decreased hearing in her left ear. Thereafter, she developed
fever and respiratory symptoms followed by gingival hyper-
trophy. Later on she developed cutaneous lesions and persis-
tent fever. Cutaneous involvement in GPA can occur in isola-
tion [11] or as part of a generalized disease. Longitudinal stud-
ies of organ involvement in more than 100 patients with GPA
have reported frequent skin involvement [4, 5, 12]. The local-
ized or limited presentation of this disease can also appear
as cutaneous lesions years before the involvement of other
systems (Table 2). Kihiczak et al. [13] described a 36-year-
old woman who was initially diagnosed as case of sarcoidosis
based on conjunctival and nasal mucosal biopsy. Later on,
atypical GPAwith granulomatous ulcers was diagnosed, after
a long protracted course [13]. In another patient, the disease
appeared as recurrent nodular lesions on legs with biopsy
suggesting nonspecific inflammation. However ten years
later, when pulmonary symptoms developed, a repeat skin
biopsy showed granulomatous vasculitis as an underlying
cause for both cutaneous and pulmonary disease [14]. In yet
another report [15], cutaneous finding included papulonodu-
lar acneiform eruption followed by development of necrotic
ulcers on forehead, arms, and buttocks. Similar evolution of
lesion was also noted in our patient who initially had nodular
lesions which later evolved into deep necrotizing ulcers.
With the established role of antineutrophil cytoplasmic
autoantibodies or ANCAs in the pathogenesis of disease and
the availability of commercially available assays, clinicians
have better tools to diagnose this complex disease [16]. ANCA
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Figure 8: After treatment with 7 weeks of prednisone and azathio-
prine.
is highly positive in patients with severe generalized disease
compared to patients with limited disease [17]. However,
commercial ANCA ELISAs have not been standardized and
vary in their sensitivity and specificity [18]. Sensitivity of
ANCA varies according to the assay used and study design,
including differences in disease severity and treatment, with
figures varying from 34% to 92% [18]. The ANCA can be
negative in limited disease as was the case in our patient.
In one study, ANCAs were detectable in only 46% of the
patients who present with limited/localized disease [19]. In
these patients the disease was confined to upper and/or lower
respiratory tract with no clinical signs of vasculitis or as early
systemic disease and no other feature of organ threatening
vasculitis or as limited disease with localized or early systemic
manifestation [19]. Patients with localized disease were also
younger with a female predominance [19]. In some patients
ANCA can never be detected despite persistent disease. Ettl
et al. [20] reported a life threatening form of GPA, in which
ANCA remained negative despite a fulminant disease course.
Then certainly there are instances where cutaneous GPA was
not associated with a positive ANCA [21, 22].
Characteristic findings that aid in establishing the diag-
nosis include histological evidence of focal necrosis, fib-
rinoid degeneration, palisading granuloma surrounded by
neutrophils and histiocytes, and granulomatous vasculitis
with lymphohistiocytic infiltrates involving muscular walls
[23]. Nonpalisading foci of granular necrosis or fibrinoid
degeneration precede the development of the typical palisad-
ing granuloma [24]. Interestingly, our patient presented with
both cutaneous and hepatic lesions so she underwent both
skin and liver biopsies. With a negative ANCA, the diagnosis
in our patient was established on histopathology. Her skin
biopsy showed superficial ulceration, vasculitis of superficial
and deep dermis comprising of fibrinoid necrosis of vessel
wall with granuloma formation and neutrophilic infiltrate
and nuclear debris consistent with cutaneous granulomatosis
with polyangiitis.
Sections examined from the liver biopsy revealed
cholestasis and multiple areas of necrosis palisaded by
epitheloid cells and chronic inflammation consistent with
granulomatous hepatitis. Liver can rarely become involved in
granulomatosis with polyangiitis where it can cause chronic
granulomatous inflammation [25–27]. It has been described
in autopsy reports of patients with GPA. In the literature
search of PubMed database, there is a report describing
granulomatous and vasculitic lesions in the liver and spleen
[28] in the autopsy whereas the nasal biopsy was negative.
The authors emphasized that the biopsymay be negative from
typical sites in atypical disease forms. In yet another report
[29], vasculitic hepatic lesion caused aneurysmal rupture
of hepatic artery. I believe that our patient presented with
an atypical, extremely rare presentation with cutaneous and
hepatic involvement which remains unexplained with other
disease processes. Although cutaneous polyarteritis nodosa
can present with nodules and leg ulcers, there is absence of
visceral involvement, integrity of muscular arteries in the
deep dermal tissue is compromised, and granulomatous
inflammation is not a feature [30].
The aim of treatment is to prevent the morbidity and
mortality associated with the disease and is usually done by
remission induction and remission maintenance [4]. Oral
cyclophosphamide (CYC) in combination with high-dose
glucocorticoids has long been the criterion standard. Due
to the toxicities associated with cyclophosphamide (CYC),
notably sterility and bladder cancer, Rituximab combined
with high-dose glucocorticoids represents an alternative for
induction of remission. It is a chimeric monoclonal anti-
CD20 IgG1 antibody that induces apoptosis of B cells.
For localized disease, methotrexate can be substituted for
CYC and added to high-dose steroids, for example, pred-
nisone 1mg/kg/day for induction of remission. Azathioprine,
leflunomide, andmethotrexate are all agents for maintenance
of remission which should be continued for at least 18
months. We recommended Rituximab to our patient for
remission induction as she had refused CYC. While she
awaited medical insurance cover for the former, treatment
was commenced with prednisone 1mg/kg/day and azathio-
prine at a dose of 2mg/kg/day with remarkable resolution of
the lesions after 7 weeks of therapy (Figure 8).
Untreated granulomatosis with polyangiitis is uniformly
fatal with mortality of up to 90% at 2 years [4]. Although
remission is generally maintained, relapses are common and
mortality remains high. A study on long term outcome of
GPA patients reported a survival time of 8.5 years [31]. It is
therefore important to identify this disease even with limited
presentation so that appropriate treatment can be initiated
and tailored for an individual patient. Mimics of cutaneous
granulomatous vasculitis should be thoroughly investigated
and excluded. Where ANCA is negative, tissue biopsy should
be obtained to arrive at the diagnosis.
Although numerous classification criteria have been
developed to aid in prompt diagnosis andmanagement, there
are always instances whereby these diseases can present in an
atypical way. The case report that we have highlighted will
prompt clinicians to consider the limited and localized forms
of granulomatosis with polyangiitis (GPA) so that the disease
is recognized early and treated effectively.
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